Patent ID: 8241632

Claim:
A formulation comprising a buffer having a pH from about 4.8 to about 5.2, a divalent cation, an excipient comprising a sugar or polyol and an effective amount of a therapeutic antibody having specific binding activity to human epidermal growth factor receptor (EGFR), wherein said therapeutic antibody is panitumumab or cetuximab and said antibody retains at least about 80% stability for up to two months in solution, and wherein said divalent cation is at least one of CaCl 2 , ZnCl 2 , MnCl 2 or MgCl 2 , wherein said divalent cation concentration is selected from about 25 mM, about 50 mM, about 75 mM, about 100 mM, or about 125 mM, and wherein said buffer is at least one of acetic acid, glutamic acid, or succinic acid, or a salt thereof, and wherein said buffer is present in a concentration of about 1 mM to about 50 mM.